Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Description

To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.

Conditions

Ventricular Tachycardia, Atrial Fibrillation

Talk to us

Study Overview

On this page

Study Details

Study overview

To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Condition
Ventricular Tachycardia
Intervention / Treatment

-

Contacts and Locations

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adults aged 18 and older
  • 2. Diagnosed with AF before age 60
  • 3. Scheduled for catheter-based AF ablation (de-novo or repeat)
  • 4. Able to provide written, informed consent
  • 5. P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
  • 1. Diagnosed with a genetic CM or arrhythmia syndrome prior to AF
  • 2. VUS in 'possibly pathogenic' subgroup (control group only)
  • 3. Pacemaker or ICD
  • 4. Previous PVC or VT ablation
  • 5. LVEF \<20%
  • 6. Prosthetic mitral or aortic valve
  • 7. Contraindication to heparin
  • 8. Prior myocardial infarction.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Vanderbilt University Medical Center,

Moore B Shoemaker, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

2027-01-01